- Brand names:
- Pharmaceutical Company:
- Condition/Indication:
- Meeting Date: November 2018
- Public Summary Document (PSD) November 2018 PBAC Meeting - PDF
- Public Summary Document (PSD) November 2018 PBAC Meeting - Word
Inotuzumab ozogamicin – November 2018
Inotuzumab Ozogamicin: Powder for I.V. infusion 1 mg; Besponsa®
Last updated
1 March 2019